Effect of neostigmine on proinflammatory cytokines secretion in septic shock
Phase 4
- Conditions
- Health Condition 1: A419- Sepsis, unspecified organism
- Registration Number
- CTRI/2023/07/055054
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients aged above 18 years
Patients having clinical features suggestive of septic shock ( Requiring vasopressor support to maintain Mean Arterial Pressure greater than 65 mm Hg)
Exclusion Criteria
1.Known absolute contraindications against cholinesterase inhibitor such as, myotonic dystrophy, depolarization block by depolarizing muscle relaxant, intoxication by irreversibly acting cholinesterase inhibitors, closed craniocerebral trauma.
2.Known relative contraindications against cholinesterase inhibitors eg bronchial asthma, brady cardia, A-V conduction disturbances. 3.Pregnant and lactating women.
4.Having undergone solid organ transplantation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the level of proinflammatory cytokine TNF-alpha in septic shock patients treated with standard therapy & those treated with neostigmine adjunctive therapy, before starting therapy, on day 3 of therapy & on day 5 of therapyTimepoint: Day 1 Day 3 Day 5 of neostigmine therapy
- Secondary Outcome Measures
Name Time Method 1. To compare change in SOFA score after 120hrs of neostigmine adjunctive therapy. 2. To compare APACHEII score after 120hr s of neostigmine adjunctive therapy. 3. To compare the mortality in both the groups after 28 days.Timepoint: Day 1,Day 2,Day 3,Day 4,Day 5,Day 28